Glajzer, Jacek
Castillo-Tong, Dan Cacsire
Richter, Rolf
Vergote, Ignace
Kulbe, Hagen
Vanderstichele, Adriaan
Ruscito, Ilary
Trillsch, Fabian
Mustea, Alexander
Kreuzinger, Caroline
Gourley, Charlie
Gabra, Hani
Taube, Eliane T.
Dorigo, Oliver
Horst, David
Keunecke, Carlotta
Baum, Joanna
Angelotti, Timothy
Sehouli, Jalid
Braicu, Elena Ioana
Funding for this research was provided by:
European Commission
Charité - Universitätsmedizin Berlin
Article History
Received: 30 September 2021
Accepted: 8 August 2022
First Online: 9 September 2022
Disclosures
: F.T. received grants, research support, advisory boards, honoraria, and travel expenses from AstraZeneca, Clovis, GSK, Medac, MSD, PharmaMar, Roche, and Tesaro. C.G. received personal fees from Roche, AstraZeneca, MSD, GSK, Tesaro, Nucana, Clovis, Foundation One, Chugai, Sierra Oncology, Cor2Ed, and Takeda; and research funding from AstraZeneca, Novartis, Aprea, Nucana, GSK, Tesaro, BerGen Bio, and Medannexin. O.D. served on advisory boards for Clovis Oncology, IMV, Tesaro, and Merck; and on the speaker bureau for AstraZeneca and Tesaro. J.S. received grants and personal fees from Astra Zeneca, Bayer, Eisai, Clovis, Olympus, Johnson and Johnson, PharmaMar, Pfizer, TEVA, Tesaro/GSK, MSD, Lilly, Roche, and Merck. E.I.B. received research funding from Bayer, Roche Diagnostics, Tesaro, GSK, snd AstraZeneca; and personal fees from AstraZeneca, Clovis, GSK, Tesaro, EISAI, RochePharma, and Roche Diagnostics. All remaining authors have declared no conflicts of interest.